TY - JOUR
T1 - A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose
AU - Rostad, Christina A.
AU - Yildirim, Inci
AU - Kao, Carol
AU - Yi, Jumi
AU - Kamidani, Satoshi
AU - Peters, Etza
AU - Stephens, Kathleen
AU - Gibson, Theda
AU - Hsiao, Hui Mien
AU - Singh, Karnail
AU - Spearman, Paul
AU - McCracken, Courtney
AU - Agbakoba, Vivien
AU - Tomashek, Kay M.
AU - Goll, Johannes B.
AU - Gelber, Casey E.
AU - Johnson, Robert A.
AU - Lee, Sujin
AU - Maner-Smith, Kristal
AU - Bosinger, Steven
AU - Ortlund, Eric A.
AU - Chen, Xuemin
AU - Anderson, Larry J.
AU - Wrammert, Jens
AU - Suthar, Mehul
AU - Rouphael, Nadine
AU - Anderson, Evan J.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Filoviruses, including Ebola, Marburg, Sudan, and Taï Forest viruses, are zoonotic pathogens that can cause severe viral hemorrhagic fever and death. Developing vaccines that provide durable, broad immunity against multiple filoviruses is a high global health priority. In this Phase 1 trial, we enrolled 60 healthy U.S. adults and evaluated the safety, reactogenicity and immunogenicity of homologous and heterologous MVA-BN®-Filo and Ad26.ZEBOV prime-boost schedules followed in select arms by MVA-BN®-Filo boost at 1 year (NCT02891980). We found that all vaccine regimens had acceptable safety and reactogenicity. The heterologous prime-boost strategy elicited superior Ebola binding and neutralizing antibody, antibody-dependent cellular cytotoxicity (ADCC), and cellular responses compared to homologous prime-boost. The MVA-BN®-Filo boost administered at 1 year resulted in robust humoral and cellular responses that persisted through 6-month follow-up. Overall, our data demonstrated that a heterologous Ad26.ZEBOV/MVA-BN®-Filo prime-boost was safe and immunogenic and established immunologic memory primed to respond after re-exposure. Clinicaltrials.gov, NCT02891980, registered September 1, 2016.
AB - Filoviruses, including Ebola, Marburg, Sudan, and Taï Forest viruses, are zoonotic pathogens that can cause severe viral hemorrhagic fever and death. Developing vaccines that provide durable, broad immunity against multiple filoviruses is a high global health priority. In this Phase 1 trial, we enrolled 60 healthy U.S. adults and evaluated the safety, reactogenicity and immunogenicity of homologous and heterologous MVA-BN®-Filo and Ad26.ZEBOV prime-boost schedules followed in select arms by MVA-BN®-Filo boost at 1 year (NCT02891980). We found that all vaccine regimens had acceptable safety and reactogenicity. The heterologous prime-boost strategy elicited superior Ebola binding and neutralizing antibody, antibody-dependent cellular cytotoxicity (ADCC), and cellular responses compared to homologous prime-boost. The MVA-BN®-Filo boost administered at 1 year resulted in robust humoral and cellular responses that persisted through 6-month follow-up. Overall, our data demonstrated that a heterologous Ad26.ZEBOV/MVA-BN®-Filo prime-boost was safe and immunogenic and established immunologic memory primed to respond after re-exposure. Clinicaltrials.gov, NCT02891980, registered September 1, 2016.
UR - http://www.scopus.com/inward/record.url?scp=85212761472&partnerID=8YFLogxK
U2 - 10.1038/s41541-024-01042-4
DO - 10.1038/s41541-024-01042-4
M3 - Article
C2 - 39715748
AN - SCOPUS:85212761472
SN - 2059-0105
VL - 9
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 255
ER -